New Drug Could Lead the Way
Promising results have emerged from a short-term Phase II multiple sclerosis (MS) clinical trial of Antegren? (natalizumab), a monoclonal antibody agent that appears to have a completely different mode of action to currently available MS treatments.
In the March 2003 PN/Paraplegia News, read about this new drug: how it works, results of the short-term clinical trial, possible side effects, and the future for Antegren and people with MS.
(Register or login to add comments.)